Need more? Try out  Advanced Search (20+ criteria)»

logo

Last Update

This profile was last updated on 10/12/2005 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Luca Paola?

Luca Dalla Paola

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Background Information

Employment History

Surgeon With the Diabetic Foot Unit

Abano Terme Hospital


Chief Diabetic Professor

Foot & Ankle Clinic


Web References(9 Total References)


Post-Approval

genetown.biospace.com [cached]


www.fdanews.com

Oculus Innovative Sciences announced that Luca Dalla Paola, a surgeon with the diabetic foot unit of the Abano Terme Hospital in Italy, recently presented the results of a 218-patient controlled clinical study that assessed the safety and efficacy of Microcyn Technology in treating diabetic foot ulcers as compared to povidone iodine (10%) antiseptic, which is often used as the "standard care" in treatment of open wounds.


Infection Control Today - Results of a Clinical Study Evaluating Treatment of Diabetic Foot Ulcers Using Microcyn Technology Presented at Wound Management Conference

www.infectioncontroltoday.com [cached]

STUTTGART, Germany -- Oculus Innovative Sciences, Inc. announces that Dr. Luca Dalla Paola, a surgeon with the diabetic foot unit of the Abano Terme Hospital in Italy, recently presented the results of a 218-patient controlled clinical study that assessed the safety and efficacy of Microcyn technology in treating diabetic foot ulcers as compared to povidone iodine (10 percent) antiseptic, which is often used as the "standard care" in treatment of open wounds.


RESULTS OF CLINICAL STUDY EVALUATING TREATMENT OF DIABETIC FOOT ULCERS USING MICROCYN™ TECHNOLOGY PRESENTED AT STUTTGART2005

www.oculusis.com [cached]

STUTTGART, GERMANY-- (October 4, 2005)- Oculus Innovative Sciences, Inc. announced that Dr. Luca Dalla Paola, a surgeon with the diabetic foot unit of the Abano Terme Hospital in Italy, recently presented the results of a 218-patient controlled clinical study that assessed the safety and efficacy of Microcyn® Technology in treating diabetic foot ulcers as compared to povidone iodine (10%) antiseptic, which is often used as the "standard care" in treatment of open wounds.


www.oculusis.com

STUTTGART, GERMANY-- (October 4, 2005)- Oculus Innovative Sciences, Inc. announced that Dr. Luca Dalla Paola, a surgeon with the diabetic foot unit of the Abano Terme Hospital in Italy, recently presented the results of a 218-patient controlled clinical study that assessed the safety and efficacy of Microcyn® Technology in treating diabetic foot ulcers as compared to povidone iodine (10%) antiseptic, which is often used as the "standard care" in treatment of open wounds.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory